Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Alto Neuroscience (ANRO) PT Lowered to $10 at Baird
October 23, 2024 6:24 AM EDTBaird analyst Brian Skorney lowered the price target on Alto Neuroscience (NYSE: ANRO) to $10.00 (from $32.00) while maintaining a Outperform rating.
The analyst comments "Lowering price target to $10 on ALTO-100 failure. Alto's first shot at its precision psychiatry approach failed to materialize... More
